A pediatric study of the pneumococcal vaccine PHiD-CV10 showed efficacy rates of 100% and 92% for the 3+1 and 2+1 vaccination schedules, respectively. “For the first time, effectiveness of a 2+1 schedule in infants was confirmed in a clinical trial,” Finnish researchers reported in the journal, The Lancet. This is good news for parents and children because this will replace PCV7 for prevention of pneumococcal disease in children. The new vaccine protects against serotype 19A, which has become the most common pneumococcal serotype and is often resistant to antibiotics. Learn more here.